Concentrated Stock

Why the decision is harder than the math

Every concentrated position is an implicit bet that the next decade will look like the last. For founders, early employees, and executives, that bet has typically paid. That is why they are now concentrated. The financial case for diversification is almost always obvious on a spreadsheet. The behavioral case is almost always harder.

The principal rarely describes the position primarily in risk terms. They describe it in identity terms. “I built this.” “I still believe in the company.” “Selling would send a signal.” All of those are real considerations. A concentration strategy that dismisses them as irrational, and pushes for immediate full diversification, will be rejected, and the position will sit untouched for another five years. A strategy that takes them seriously and designs around them will actually get implemented.

The real options

There is no optimal answer. There are eight or nine distinct tools, each suited to a different combination of tax position, timeline, and emotional constraint.

Planned sales. A multi-year sale plan, timed against low-income years, secondary windows, or known liquidity events. Works best for moderately concentrated positions below $10M and for executives with regular trading windows. Often the cleanest answer, and almost always underused.

10b5-1 plans (US) and equivalents. Pre-established trading plans that execute automatically regardless of subsequent material non-public information. The SEC’s 2023 revisions tightened cooling-off periods and disclosure. The mechanic remains the standard for executives who want predictable selling without blackout-window constraints.

Exchange funds. Contribute concentrated stock into a pooled fund alongside other concentrated positions. Receive an interest in the diversified pool without triggering immediate capital gains. Seven-year holding period required. Historically $25M+ minimums; several current sponsors operate in the $5M to $15M range. The qualifying real estate sleeve (typically 20 to 25 percent) is structural and limits pure equity exposure.

Structured collars. Purchase a put and sell a call at different strikes to bracket the position’s value. Locks in a floor while capping upside. Particularly useful for executives approaching lockup expiry who cannot sell yet but want to protect against a drawdown. Tax treatment is position-specific. Constructive sale rules (US) and equivalents in other jurisdictions limit how tight the collar can be.

Variable prepaid forwards. The executive receives cash up-front (often 75 to 90 percent of position value) in exchange for a future delivery of shares within a specified price range. Defers the capital gain, generates liquidity, and preserves some upside above a cap. Structurally complex and increasingly scrutinized. The economics must clearly fall within safe-harbor rules.

Charitable vehicles. Donate appreciated stock directly to a DAF, private foundation, or CRT. The donation value is fair market, the capital gain is avoided, and the deduction (subject to AGI limits in most jurisdictions) offsets other income. For founders with genuine charitable intent, this is often the highest-return tax move available.

Gifts to grantor trusts and GRATs. Move concentrated pre-liquidity stock into a GRAT or IDGT before a major appreciation event. The grantor reports the income. The trust receives the growth. Requires early action, generally before a transaction is priced or announced.

Section 1202 / QSBS stacking. For founders of qualifying US C-corporations, structured gifts to family members and non-grantor trusts can multiply the per-taxpayer QSBS exclusion. A $10M exclusion becomes $30M, $50M, or more with careful stacking and the right documentation.

Hedging with options. A cheaper-than-collar approach. Buy protective puts without selling calls. Pure cost, no upside cap. Appropriate for the window between wanting to protect and being able to sell.

Borrowing against the position. Securities-backed lines of credit against the concentrated stock provide liquidity without triggering a realization event. Low cost in normal markets. Catastrophic if the stock drops into a margin call. Should be a complement to a diversification plan rather than a substitute.

Timing windows that dominate outcomes

The decision is not “whether to diversify” but “when, and through what window.”

Pre-IPO (roughly 12 to 36 months before). The highest-leverage window for freeze transactions. Gifts to grantor trusts, QSBS structuring, and the early setup of charitable vehicles should happen here. The valuation is still low enough that moving stock out of the estate is cheap. The liquidity has not arrived yet to crystallize tax bills.

Lockup (typically 180 days post-IPO). The executive is holding a public stock they cannot sell. Hedging (collars, puts) and 10b5-1 plans established pre-lockup are the primary levers. The market’s behavior during lockup is often dramatic, and typically downward, which makes the hedge decision consequential.

Post-lockup (first 12 to 24 months). The largest volume of selling typically happens here. The key decisions are the rate of diversification, tax staging, and whether to participate in structured products (exchange funds, variable prepaids). Executives who have not already set up GRATs or charitable structures often wish they had.

Secondary windows. Tender offers, company-led secondaries, and structured liquidity events open specific windows that close quickly. Decisions made inside these windows (how much to sell, through what structure) often set the tax profile for years.

Long-tail holding (5+ years post-liquidity). The remaining concentration. Many founders and executives drift into this phase without a plan, holding a declining-relevance stake in the company for emotional rather than financial reasons. The tools at this stage are the same (exchange funds, charitable vehicles, collars) but the urgency has faded.

What goes wrong

Waiting for the peak. Every founder believes, at some level, that the stock is still going up. Selling is therefore always premature. The households that escape this trap commit in advance to diversification milestones, tied to price, time, or net worth thresholds, before the emotional moment arrives.

Using the wrong tool. An exchange fund for a position the principal will want back (wrong: seven-year lockup). A collar for a position the principal is willing to sell (wrong: costs money without fully solving the problem). Borrowing against a highly volatile position (wrong: margin call exposure).

Missing the freeze window. The tax-efficient transfer vehicles (GRATs, IDGTs, QSBS stacking) are disproportionately valuable before a liquidity event, not after. Principals who wait until after the sale to ask about estate planning routinely leave seven-figure tax savings on the table.

Signaling problems. Insider-sale disclosures, 10b5-1 plan announcements, and public filings can send signals to the market that the executive did not intend. Sophisticated plans coordinate with the company’s investor relations function rather than against it.

Treating the position as the whole portfolio. A concentration strategy built in isolation from the rest of the balance sheet misses obvious coordination moves. Charitable vehicle funding during high-income years. Loss harvesting in the non-concentrated portfolio to offset gains from selling. Asset-location optimization around the new cash balance.

Advanced patterns

Stacked diversification. Combining multiple tools: some planned sales, some exchange fund participation, some collared positions, some GRAT or trust holdings. The right mix is portfolio-specific. The principle is that no single tool is usually the whole answer.

Pre-lockup structuring for founders. The 12 months before an IPO is the highest-density planning window in most founders’ lives. Work that routinely happens here: founder stock gifts to trusts, QSBS documentation review, charitable vehicle setup, hedging strategy selection, post-lockup sale-plan drafting, and coordination with corporate counsel on 10b5-1 plan timing.

Concentrated-position-specific private credit. Lenders who will lend against pre-IPO positions, typically at high LTV but with specific provisions around lockup and secondary events. The terms vary dramatically. A handful of lenders do this cleanly. Others have predatory terms.

Multi-jurisdictional structuring. For founders with dual residency or recent international moves, the concentration position typically spans jurisdictions. The right answer often involves entity restructuring or trust situs decisions before the liquidity event, many of which are irreversible once the transaction prices.

Where to go deeper

Concentrated-position decisions are personal and dollar-specific. Peer groups for founders (Hampton, Enter the Index) regularly surface real case studies from members who have navigated IPO lockup, secondary sales, and structured hedges. Decisions tend to be better when informed by two or three peers who have been through the specific combination of tools under consideration. For locale-specific mechanics (QSBS, SEIS/EIS, employee option structures, capital gains regimes), see the hub-specific versions of this topic.